We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Horizon Therapeutics Public Limited Company | NASDAQ:HZNP | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 116.30 | 116.31 | 116.30 | 0 | 01:00:00 |
From May 2023 to May 2024
14:16 ET -- Amgen and Horizon Therapeutics are among the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The Federal Trade Commission agreed to end its legal challenge of Amgen's $27.8 billion deal to buy Horizon. The pact also dismisses the antitrust claims of six states that joined the FTC seeking to block the transaction over concerns that Amgen would illegally bundle its products with Horizon's medicines for thyroid eye disease and gout. The companies expect to close the deal early in the fourth quarter. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
September 01, 2023 14:31 ET (18:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Horizon Therapeutics Pub... Chart |
1 Month Horizon Therapeutics Pub... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
